Medicine Recommendations

Primary and secondary prevention of cardiovascular disease

Bowel obstruction - nausea and vomiting associated with bowel obstruction

Parkinson’s disease – adjunctive therapy in adults with end-of-dose motor fluctuations who cannot be stabilised on preparations of levodopa/DOPA decarboxylase inhibitors

Management of patients with skin and soft tissue infections

For Non – Cystic Fibrosis Bronchiectasis

Influenza treatment & prophylaxis (NICE TA158 & 168)

NICE TA158 - Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza

NICE TA168 - Amantadine, oseltamivir and zanamivir for the treatment of influenza

Vulvovaginal or vaginal atrophy in postmenopausal women

Anxiety (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of epilepsy

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Pain

Breathlessness in the last days of life (on the advice of a specialist)

Restless Legs Syndrome

Chronic pain

For cluster headaches - under review

Breathlessness

Treating moderately to severely active ulcerative colitis - NICE TA828

NICE TA828 - Ozanimod for treating moderately to severely active ulcerative colitis

Palforzia for treating peanut allergy in children and young people (NICE TA769)

NICE TA769 - Palforzia for treating peanut allergy in children and young people

Schizophrenia

MHRA Drug Safety Update - Risperidone and paliperidone: risk of floppy iris syndrome

Maintenance treatment of schizophrenia in adult patients

Treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products